

WILLIAM DAMESHEK and FREDERICK GUNZ'S

LEUKEMIA

FOURTH EDITION

Edited by

Frederick W. Gunz, M.D., Ph.D.

Consulting Hematologist

Sydney Hospital and

Consultant Scientist

Kanematsu Memorial Institute

Sydney, Australia

Edward S. Henderson, M.D.

Chief of Medical Oncology

Roswell Park Memorial Institute and

Professor of Medicine

State University of New York

Buffalo, New York



G&S

GRUNE & STRATTON

A Subsidiary of Harcourt Brace Jovanovich, Publishers

New York

London

Paris

San Diego

San Francisco

São Paulo

Sydney

Tokyo

Toronto

© 1983 by Grune & Stratton, Inc.

All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher.

Grune & Stratton, Inc.

111 Fifth Avenue

New York, New York 10003

Distributed in the United Kingdom by

Academic Press Inc. (London) Ltd.

24/28 Oval Road, London NW 1

Library of Congress Catalog Number 82-48968

International Standard Book Number 0-8089-1513-4

Printed in the United States of America

Preface

It is nearly a quarter century since the first edition of *Leukemia* appeared. At that time leukemia was always a death sentence, in children as well as adults. Huge gaps existed in the basic knowledge of normal blood cells and their pathologically perverted forms, and hematologic techniques, both for routine investigations and research, were relatively undeveloped. The lymphocyte was still a mystery, its life cycle and functions little better understood than in the times of William Hewson. The human chromosome complement stood officially at 48.

Subsequent editions of *Leukemia* have chronicled the remarkable advances that have occurred since then; this edition continues that account. Because of the vast burgeoning of work being done on so many aspects of the leukemia problem—and a problem it remains—it has become increasingly difficult for a few individuals to give an account that is intelligible to nonspecialists as well as those with a special interest in the disease. The decision to convert *Leukemia* into a multiauthor production, with leading workers from the United States, Europe, and Australia writing chapters on their own special subjects therefore became inescapable. The editors owe a profound debt of gratitude to all those who have contributed so willingly to the common task.

William Dameshek, the original senior author of this work, set its tone by stressing, in the first Preface, that it was neither an encyclopedia nor a textbook but a monograph for those, especially internists, pediatricians and pathologists, wishing to know more about leukemia as a whole. This aim of making the book more readable rather than merely a source for consultation was maintained under the coeditorship of Albert Baikie, whose untimely death occurred soon after the publication of the third edition. The current editors have tried their best to continue in this tradition.

Compared with previous editions, the book has been almost completely rewritten. Changes have also been made in the selection of subjects and in emphasis. For example, general chapters on the lympho- and immunoproliferative disorders have been omitted, but newly recognized conditions such as hairy cell leukemia are extensively discussed. Increased scope has been given to work in areas such as immunology and clonality of leukemia where rapid progress has recently occurred. The morphology of leukemic cells and its perhaps surprisingly rediscovered prognostic significance receive more detailed attention. Although advances are reported from many fields and much has changed and

is now clearer, the need for further decisive progress, both in the basic study of leukemia and its practical management, remains urgent.

We are grateful to many colleagues and publishers who permitted reproduction of published charts and figures or supplied us with original material for illustrations. Their generosity is acknowledged in the legends to the relevant figures. We wish also to acknowledge the labors of our publishers, who surmounted innumerable problems, not the least of which were the vagaries of postal services on three continents. Very special thanks go to our secretaries, particularly to Ms. Patricia Stronka, not only for innumerable hours of typing but for her role in organizing, posting, and telephoning on our behalf.

Finally, we would like to thank our spouses, Jean and Barbara, for forgiving the many hours taken from all of our lives by the work on the fourth edition.

But now our task is finished, and the baton is passed on to the reader. We hope that this volume will provide you with both the information and the urge to join in the clinical, scientific, and humanitarian efforts to understand, manage, and prevent the dreadful illness known as leukemia.

Frederick W. Grunz, M.D., Ph.D.
Edward S. Henderson, M.D.

Contributors

John M. Bennett, M.D., Professor of Oncology in Medicine, University of Rochester School of Medicine and Dentistry, Department of Medicine and University of Rochester Cancer Center, Rochester, New York

W. Archie Bleyer, M.D., Associate Professor of Pediatrics, Children's Orthopedic Hospital and Medical Center, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, Washington

J. Bréton-Gorius, Ph.D., Director of Research INSERM, Unité de Recherches sur les Anémies, Hôpital Henri Mondor, Créteil, France

George P. Canellos, M.D., Chief of Division of Medical Oncology, Sidney Farber Cancer Institute and Department of Medicine, Harvard Medical School, Boston, Massachusetts

Daniel Catovsky, M.D., MRC Path., Senior Lecturer in Haematology and Medicine, MRC Leukaemia Unit, Royal Postgraduate Medical School, London, United Kingdom

Patrick J. Creaven, M.B., B.S., Ph.D., Chief, Department of Clinical Pharmacology and Therapeutics, Roswell Park Memorial Institute, and Research Associate Professor, Roswell Park Memorial Institute, Division of the Graduate School, State University of New York, Buffalo, New York

Alexander Fefer, M.D., Professor of Medicine, Department of Medicine, Division of Oncology, University of Washington School of Medicine, Seattle, Washington

Philip J. Fialkow, M.D., Professor and Chairman, Department of Medicine, University of Washington, and Physician-in-Chief, University Hospital, Seattle, Washington

Robert C. Gallo, M.D., Chief, Laboratory of Tumor Cell Biology, National Cancer Institute, Bethesda, Maryland

O. Margaret Garson, F.R.A.C.P., F.R.C.P.A., Director, Cytogenetics Unit, and Senior Associate, University of Melbourne, Department of Medicine, St. Vincent's Hospital, Melbourne, Australia

Harvey R. Gralnick, M.D., Chief, Hematology Service, National Institutes of Health, Bethesda, Maryland

Hans W. Grünwald, M.D., Chief, Division of Hematology, Queens Hospital Center Affiliation of the Long Island Jewish-Hillside Medical Center and Assistant Professor of Medicine, State University of New York, Stony Brook, New York

Frederick W. Gunz, M.D., Ph.D., Consulting Hematologist, Sydney Hospital, and Consultant Scientist, Kanematsu Memorial Institute, Sydney, Australia

Edward S. Henderson, M.D., Chief of Medical Oncology, Roswell Park Memorial Institute, and Professor of Medicine, State University of New York, Buffalo, New York

Peter Hersey, F.R.A.C.P., D. Phil., Clinical Immunologist, Kanematsu Memorial Institute, Sydney Hospital, Sydney, Australia

Donald J. Higby, M.D., Associate Chief, Department of Medical Oncology, Roswell Park Memorial Institute, and Associate Research Professor of Medicine, State University of New York, Buffalo, New York

Henry S. Kaplan, M.D., Maureen Lyles D'Ambrogio Professor, Department of Radiology, Stanford University School of Medicine, Stanford, California

Robert J. Mayer, M.D., Division of Medical Oncology, Sidney Farber Cancer Institute, and Assistant Professor of Medicine, Department of Medicine, Harvard Medical School, Boston, Massachusetts

Jun Minowada, M.D., D.M.S., Head, Cell Culture Laboratory, and Associate Chief, Department of Molecular Immunology, Roswell Park Memorial Institute, New York State Department of Health, Buffalo, New York

Harvey D. Preisler, M.D., Associate Chief, Department of Medical Oncology, Roswell Park Memorial Institute, Research Associate Professor of Medicine, State University of New York, Buffalo, New York

Fred Rosner, M.D., Director, Department of Medicine, Queens Hospital Center Affiliation of the Long Island Jewish-Hillside Medical Center, and Professor of Medicine, State University of New York, Stony Brook, New York

Yousef M. Rustum, Ph.D., Associate Director, Department of Experimental Therapeutics and Grace Cancer Drug Center, Roswell Park Memorial Institute, and Research Associate Professor, Department of Pharmacology, Roswell Park Memorial Institute Division of the Graduate School, State University of New York, Buffalo, New York

Stephen C. Schimpff, M.D., Professor of Medicine and Director, University of Maryland Cancer Center, Baltimore, Maryland

John F. Smyth, M.D., M.Sc., F.R.C.P.E., Imperial Cancer Research Fund, Professor of Medical Oncology and Department of Clinical Oncology, University of Edinburgh, Edinburgh, Scotland

Alexander S. D. Spiers, M.D., Ph.D., Professor of Medicine, Division of Oncology, Department of Medicine, Albany Medical College, Albany, New York

E. Donnall Thomas, M.D., Fred Hutchinson Cancer Research Center, and Professor of Medicine, Department of Medicine, and Chief, Division of Oncology, University of Washington School of Medicine, Seattle, Washington

Paul C. Vincent, M.D., Director of Medical Research, Kanematsu Memorial Institute, Sydney Hospital, Sydney, Australia

Flossie Wong-Staal, Senior Investigator, Laboratory of Tumor Cell Biology, National Cancer Institute, N.I.H., Bethesda, Maryland

Contents

Preface	xxi
Contributors	xxiii

I INTRODUCTION

1 Leukemia in the Past	3
Frederick W. Gunz	
2 Definition and Classification	13
Edward S. Henderson	
3 Epidemiology	17
Frederick W. Gunz	
Incidence and Mortality of Leukemia	17
Definition and Sources	17
Geographic, Racial, and Social Distribution	18
Total Prevalence of Leukemia	22
All Leukemias	22
Type Distribution	24
Age Distribution	28
Sex Distribution	31
Is the Incidence of Leukemia Rising?	35
Leukemia Clustering	42

II THE NATURE OF LEUKEMIA

4 Pathophysiology	49
Paul C. Vincent	

AL	52
Leukemic Cell Abnormalities	52
Effect on Normal Cells	53
Effects on Body Physiology	54
Invasive and Infiltrative Effects	54
CGL	54
Leukemic Cell Abnormalities	54
Effect on Normal Cells	55
Physiologic and Infiltrative Effects	55
CLL	56
Leukemic Cell Abnormalities	56
Effect on Normal Cells	57
Physiologic and Infiltrative Effects	57
HCL	58
Leukemic Cell Abnormalities	58
Effect on Normal Cells	58
Physiologic and Infiltrative Effects	58
5 Clonal Development and Stem Cell Origin of Leukemias and Related Disorders	63
Philip J. Fialkow	
Chronic Myeloproliferative Disorders	64
Chronic Granulocytic Leukemia	64
Clonal Development 65 · Stem Cell Origin 66 · Blastic Transformation 66 · Residual Normal Stem Cells 66 · Cause and Pathogenesis 67 · Ph ¹ -negative CGL 68	
Agnogenic Myeloid Metaplasia with Myelofibrosis	68
Stem Cell Origin and Clonal Development 68 · Myelofibrosis 68	
Essential Thrombocythemia	69
Polycythemia Vera	69
Stem Cell Origin and Clonal Development 69 · Suppression of Normal Stem Cells 69	
Regulatory Abnormalities	70
Acute Leukemias	71
Myelocytic	71
Lymphocytic	72
Chronic Lymphoproliferative Blood Cell Neoplasms	72
Ig Mosaicism	72
Chronic Lymphocytic	73
Multiple Myeloma	73
Waldenström's Macroglobulinemia	74
Concluding Remarks	74
6 Kinetics of Leukemia and Control of Cell Division and Replication	77
Paul C. Vincent	
Normal Granulocyte Kinetics	78
Stem Cells	78
Feedback Control	80
Recognizable Granulocytic Precursors in the Marrow	81
Blood Granulocytes	83

Kinetics in AL	83
Stem Cells	84
In Vitro Study of CFU-C	85
Leukemic Cell Activity in Stimulating In Vitro Colony Growth of Marrow	86
Kinetics of Recognizable Leukemic Cells	86
Proliferating and Nonproliferating Pools 86 · Kinetics of Leukemic Cells in the Central Nervous System 89 · Time Parameters of Division and Rates of Production 89 · Peripheral Blood Cell Kinetics 89 · Leukemic Blast Kinetics at Different Stages of Disease 90	
Relationship of Normal and Leukemic Cells	90
Kinetics and Chemotherapy	91
Prognostic Significance 93 · Effect of Chemotherapy on Normal Cells 94	
Kinetics in CGL	94
Stem Cells	94
Feedback Control	95
Recognizable Granulopoietic Precursors	96
³HTdR Studies	96
Myeloblasts 96 · Promyelocytes 97 · Myelocytes 97	
Splenic Granulopoiesis	97
Cell Traffic	97
Proliferative Cells in the Blood	98
Nondividing Granulocytic Precursors	98
Liquid Scintillation Blood Studies after ³ HTdR	99
DFP Studies	99
In Vitro Labeling with DF ³² P 99 · Comparison with Results Obtained Using ⁵¹ Cr-labeled Cells 100 · Cross-transfusion Studies with DF ³² P-labeled Cells 100 · DF ³² P Studies During Remission 100 · In Vivo Labeling with ³ HDfP 101 · In Vivo Studies with DF ³² P 101	
Leukapheresis Studies	101
Other Studies	101
Studies in CGL-BC	101
Kinetics in Chronic Lymphocytic Leukemia	102
Normal Lymphocyte Kinetics	102
Leukemic Lymphocyte Kinetics	103
7 Immunology of Leukemic Cells	119
Jun Minowada	
Markers of Human Hematopoietic Cells	121
Human Leukemia-Lymphoma Cell Lines	124
Marker Profiles of Human Leukemia Shown by Multiple Marker Analysis	132
Clinical and Theoretic Implications	134
8 Biochemistry of Leukemic Cells	141
John F. Smyth	
Purine Metabolism	145
ADA	147
PNP	148

Pyrimidine Metabolism	148
DNA Polymerases	149
9 Ultrastructure of Leukemic Cells	155
Janine Bréton-Gorius	
Normal Maturation	155
Leukemic Cell Ultrastructure	158
Chronic Lymphocytic Leukemias	158
Acute Lymphoblastic Leukemias	158
Chronic Granulocytic Leukemia	159
Acute Myeloid Leukemia	159
Acute Megakaryoblastic Leukemia	161
10 Cytogenetics of Leukemic Cells	167
O. Margaret Garson	
Methods	167
CGL	168
Ph ¹ -Negative CGL	170
CGL-BC	170
AL	172
AML	175
Abnormalities in AML and APL	175
Acute Erythroleukemia	180
ALL	180
Ph ¹ Chromosome in AL	182
Secondary AL	182
Preleukemia	184
Myeloproliferative Disorders	184
Lymphoproliferative Disorders	186
Chronic Lymphocytic Leukemia	186
Lymphoma	186
Value of Chromosome Studies	189
11 Pathology of the Leukemic Tissue	197
Edward S. Henderson and Frederick W. Gunz	
Hematopoietic and Lymphatic Organ Involvement	197
Spleen	197
Liver	204
Lymph Nodes	204
Bone, Joint, and Muscle Involvement	206
Transverse Bands of Diminished Density	208
Lesions	209
Bone Formation	209
Osteolytic	
Osteosclerotic Lesions	209
Subperiosteal New	
Chloromas (Myeloblastomas)	211
Muscle Involvement	215
Nervous System Involvement	216
Skin Involvement	219
GI Involvement	222
Heart Involvement	226

	Mouth and the Respiratory System Involvement	230
	Mouth and Throat	230
	Lungs	230
	Mikulicz's Syndrome	234
	Ocular Involvement	235
	Urogenital Tract Involvement	236
	Other Organ Involvement	240
12	Special Clinical and Laboratory Manifestations	247
	Paul C. Vincent	
	Anemia	247
	Decreased RBC Production	247
	Ineffective Erythropoiesis	248
	Hemolysis	251
	Posthemorrhagic Anemia	256
	Anemia Caused by Therapeutic Agents	256
	The Hemorrhagic State	258
	Platelets	258
	Disseminated Intravascular Coagulation	258
	Other Coagulation Factors	260
	Purine Metabolism	260
	Indices of Leukocyte Turnover and Mass	264
	Vitamin B₁₂ and Folic Acid	269
	Terminal Deoxynucleotidyl Transferase	271
	Flow Cytometry	271
	Blood Groups and HLA Tissue Types	272
	III ETIOLOGY OF LEUKEMIA	
13	Etiology of Leukemia: A Persisting Puzzle	287
	Edward S. Henderson	
14	Animal Models of Leukemia and Lymphoma	289
	Henry S. Kaplan	
	Morphology, Histogenesis, and Clinical Manifestations	289
	Etiologic Agents	292
	Epidemiology	295
	Mice	295
	Cats	295
	Cattle	296
	Apes	297
	Genetic and Constitutional Influences on Susceptibility	297
	Target Cells for Neoplastic Transformation	299
	Immunologic Interactions	300
	Altered Properties of Neoplastic Cells	301
	Experimental Therapeutics	302
15	Genetic Factors in Human Leukemia	313
	Frederick W. Gunz	
	Family Studies	313
	Twin Studies	318

Congenital Chromosome Abnormalities and Leukemia	319
Other Congenital Abnormalities and Leukemia	323
Interpretation of Genetic Studies	324
16 Retroviruses and Leukemia	329
Flossie Wong-Staal and Robert C. Gallo	
Classification	330
Endogenous Viruses	331
Chronic Leukemia Viruses	334
Acute Leukemia Viruses	335
Sarcoma Viruses	335
Animal Models with Clear Viral Etiology	337
Avian Leukemia	338
Lymphoid Leukemia-Lymphoma in Wild Mice	339
Feline Leukemia	339
Bovine Leukosis	340
Gibbon Ape Leukemia	341
In Vivo and In Vitro Neoplastic Transformation with Type C Viruses Under Laboratory Conditions	342
Possible Mechanisms for Leukemogenesis	343
Leuk Genes of the AL Viruses	343
Nondefective Viruses	345
Recombinant Viruses	345
Importance of the Viral C Region for Leukemogenicity	345
Indirect Mechanisms	356
Virus-negative Cat Leukemia: Possible In Vivo Model	346
"Transformation" of Human Lymphocytes by Primate Type C Viruses (GaLV-SSAV): Possible In Vitro Model	347
Retroviruses and Human Leukemias and Lymphomas	347
Reverse Transcriptase	348
Other Biochemical and Immunologic Studies	348
Human Virus Isolates Related to Other Primate Retroviruses	350
Recent Isolations of Novel Type C Oncornaviruses from Human T Cell Leukemia and Lymphoma	350
Discovery of T Cell Growth Factor and Normal T Cell Growth	350
Growth of T Cells from Patients with T Cell Lymphomas and Leukemias	351
Isolation of New Type C Viruses	351
Retroviruses Crucial to Understanding of Leukemia	352
17 Ionizing Radiations and Human Leukemia	359
Frederick W. Gunz	
Radiation Leukemogenesis	360
Leukemia After Exposure to Atomic Radiation	360
Leukemia After Exposure to Medical Radiations	364
Leukemia After Occupational Radiation Exposure	367
Risk of Producing Leukemia by Ionizing Radiation	369
18 Chemicals and Leukemia	375
Fred Rosner and Hans W. Grünwald	
Review of the Literature	376
Multiple Myeloma	376
Waldenström's Macroglobulinemia	379

Other Paraproteinemias	379
Hodgkin's Disease	379
Non-Hodgkin's Lymphoma	380
Mycosis Fungoides	380
Chronic Lymphocytic Leukemia	380
Acute Lymphocytic Leukemia	380
Breast Cancer	380
Ovarian Cancer	381
Other Neoplasms	381
Nonneoplastic Diseases	382
Late-occurring AL: Characteristic Features	382

IV DIAGNOSIS OF LEUKEMIA

19 Clinical Diagnosis	393
Edward S. Henderson	
Diagnosis: Subcategorization and Delineation	393
Recapitulation of Pathophysiology	396
Individuals at Increased Risk	397
Genetic Traits 397 · Acquired Disease 400 · Radiation Exposure 401 · Chemical Exposure 402	
Diagnosis: General Features	402
Specific Organ-Site Related Signs and Symptoms	406
Oral Cavity 406 · Head and Neck 406 · Cardiorespiratory System 407 · GI Tract 407 · Genitourinary System 407 · Skin Involvement 408 · Neurologic Problems 408 · Ophthalmic Problems 411 · Metabolic Abnormalities 412 · Fluid Electrolyte and Acid-Base Disturbances 414	
Roentgenographic and Radionuclide Scan Findings	415
Leukemia Markers	416
Cytoplasmic Markers	419
Serum Factors	421
Major Forms of Leukemia	421
ALs	421
ALL 421 · cALL 421 · Pre-B-cell ALL 425 · T-cell ALL 425 · B-cell ALL 426 · AUL 426 · AML 426 · APL 428 · AMML 428 · AMoL 428 · AEL (DiGuglielmo's Syndrome) 429	
Preleukemic Syndromes	429
CLs	430
CGL 430 · Ph ¹ -negative CGL 431 · BC 431 · CLL 434 · B-cell CLL 435 · T-cell CLL 43 · Acute Leukemic Termination 435	
Unusual Forms of Leukemia	436
Hand Mirror Cell Leukemia	436
Megakaryoblastic Leukemia	436
HCL	436
Eosinophilic Leukemia	437
Basophilic Leukemia	438
Plasma Cell Leukemia	438
Sézary Syndrome	438
Congenital Leukemia and Pseudoleukemia	439
Differential Diagnosis	440

20 Leukemia Morphology and Cytochemistry	463
John M. Bennett	
Definition and Classification	463
ALLs	464
ALL	465
Cytochemistry 466 · Terminal Deoxynucleotidyl Transferase 466 ·	
Anti-ALL Sera 467	
AML	467
AML Without Maturation 468 · AML with Maturation 468 ·	
Hypergranular APL 468 · AMML 468 · AMoL 469	
Acute Erythroleukemia	469
Mast Cell Leukemia	469
Acute Myelosclerosis	470
CLS	470
CGL	470
Chronic Indolent (Benign) Phase 470 · Accelerated (Preterminal plus Terminal) Phase 470	
CLL	471
Sézary Syndrome	471
Variants of CLL	472
HCL	472
Chronic Myelomonocytic Leukemia	472
Future Directions	473

V GENERAL CONSIDERATIONS OF TREATMENT

21 Terminology and Perspectives	489
Edward S. Henderson	
Terminology	489
General Patient Management	492
Treatment Modalities	493
22 Principles of Chemotherapy: Drugs and Biochemical Determinants	495
Patrick J. Creaven and Youcef M. Rustum	
Basic Concepts	495
Biologic and Biochemical Considerations	495
Pharmacologic Considerations	498
Absorption 499 · Distribution 499 · Metabolism 501	
Excretion 501 · Influencing Factors 502	
Classification of Antitumor Agents	503
Drugs Active Against Leukemia	504
Alkylating Agents	504
Mechlorethamine 507 · Chlorambucil 508 ·	
Cyclophosphamide 508 · Busulfan 510 · BCNU 511 ·	
DBM 512	
Antimetabolites	512
6-Mercaptopurine 514 · 6-Thioguanine 515 · Ara-C 516	
5-Azacytidine 517 · MTX 518	
Anthracycline Antibiotics	520

<i>Vinca</i> Alkaloids	522
Epipodophyllotoxins	523
Miscellaneous Compounds	524
L-Asparaginase 524 · Hydroxyurea 525	
Methylglyoxal-bis-guanyldrazone 525	
Adrenocortical Hormones	526
Biochemical and Pharmacologic Determinants of Drug Action	527
Target Cell Determinants of Antimetabolite Action	528
Determinants of Anthracycline Action	529
23 Immunotherapy	543
Peter Hersey	
Immunotherapy Studies in AML	544
Chemotherapy Plus Immunotherapy versus Chemotherapy Alone	544
Immunotherapy Alone Versus Maintenance Treatment	546
Differences in Centers' Results in Relation to Differences in Protocols	546
Other Immunotherapy Studies	548
Mode of Action of Immunotherapy	548
Immunotherapy Studies in ALL	549
Immunotherapy of CL	550
Future Trends	551
Induction of NK Activity Against Leukemia Cells	551
Specific Active Immunotherapy	552
The Role of Interleukins 552	
24 Marrow Transplantation in the Treatment of Leukemia	557
E. Donnall Thomas and Alexander Fefer	
Histocompatibility	557
Procedure	558
Preparation of Recipient	558
Marrow Aspiration and Infusion	559
Supportive Care	559
Prevention and Treatment of Infection	559
Transfusion Support	560
Clinical Results	560
Marrow Transplantation from Identical Twins	560
Marrow Transplantation from HLA-identical Donors	562
Marrow Transplantation from HLA-identical Siblings in CGL	566
Marrow Transplantation from Haploidentical Donors	566
Autologous Marrow Transplantation	567
Major Problems in Marrow Transplantation from HLA-identical Donors	567
GVHD	567
Acute GVHD 567 · Chronic GVHD 567	
Opportunistic Infections and Interstitial Pneumonia	568
Recurrent Leukemia	569
Marrow Transplantation for Other Diseases	569
Patient Selection for Marrow Transplantation	570